All News

The AUA has voiced its support for newly introduced legislation designed to address urotrauma, a growing concern among active military personnel and veterans.

Focal laser ablation is safe and can be performed without the troubling complications associated with more aggressive therapies for low-risk prostate cancer, results of a small phase I study indicate.

More stringent criteria may be needed for African-American men with prostate cancer when considering active surveillance for their disease, new research from The Cancer Institute of New Jersey, New Brunswick suggests.

Placement of an inflatable penile prosthesis (IPP) approximately 3 months after T-shunt surgery in men with acute ischemic priapism and refractory erectile dysfunction is associated with favorable outcomes at 1 year, according to data from a small series of such patients.

Use of tivozanib, an experimental tyrosine kinase inhibitor (TKI) with increased specificity and potency for the vascular endothelial growth factor (VEGF) receptor, as initial targeted therapy for patients with advanced renal cell carcinoma did not translate into improved overall survival compared with sorafenib (Nexavar) in a phase III clinical trial.

A recent study highlights huge price swings in patient charges for the 10 most common outpatient conditions-including kidney stones and urinary tract infection-in emergency rooms across the country.

Nearly three-quarters of patients undergoing radiation therapy for prostate cancer had no evidence of the disease at 25 years’ follow-up, the authors of a study from Radiotherapy Clinics of Georgia, Atlanta recently reported.

OnabotulinumtoxinA (Botox) has earned FDA approval for the treatment of overactive bladder in adults who cannot use or don't adequately respond to anticholinergic drugs, and its potential uses in urology may not end there.

Publication of the Value of Urodynamic Evaluation study has drawn attention to whether urodynamics improves patient outcomes when added to an office evaluation of stress urinary incontinence before surgical intervention.

Drugs and devices in the pipeline from Bayer Healthcare, AVEO Oncology, Astellas Pharma Inc., Trimel Pharmaceuticals Corp., OncoGenex Pharmaceuticals, Inc., Nymox Pharmaceutical Corp., Spectrum Pharmaceuticals, and Tengion, Inc.

Recent analyses of urodynamic testing data indicate that both autologous fascial pubovaginal sling and synthetic midurethral sling procedures decrease maximum flow rate and increase bladder outlet resistance, but the pubovaginal sling was found to create more bladder outlet resistance.

One in five U.S. physicians are over 65 years of age as of 2010, the American Medical Association reports. Some experts say that regular cognitive and physical screenings are needed once physicians reach 65 or 70 years of age, but no standardized screening is available. Age, of course, is not always a negative factor, says urologist Sivaprasad D. Madduri, MD.

Many synthetic chemicals, untested for their disrupting effects on the hormone system, may have significant health implications, including contributing to the development of prostate cancer in men and undescended testes in young males.

Three "field effect" epigenetic biomarkers were found to be more prevalent in histologically benign biopsy cores from prostate cancer patients diagnosed with Gleason score 7 prostate cancer than in those with low-volume Gleason 6 disease, researchers reported at the Genitourinary Cancers Symposium in Orlando, FL.